Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2004
The purpose of this study is to evaluate the safety of and immune response to an alphavirus replicon, HIV-1 subtype C gag vaccine, AVX101, in HIV uninfected adults in the United States, South Africa, and Botswana.
Epistemonikos ID: 33982e77a60573e08ce202c371542b8f5d1f7080
First added on: Dec 01, 2021